Skip to content
ChickenStockChickenStock
ResearchRARE
Ultragenyx Pharmaceutical logo

Ultragenyx Pharmaceutical (RARE) stock

NASDAQ

$16.69+4.97%(+0.79)

As of the Nov 17, 2026 close (U.S. Eastern)

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-3.25x

Net loss — not comparable

P/B

—

P/S

2.33x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Revenue increased 8.1% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 4, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

5 SEC filings
  • Horn HowardChief Financial Officer · Oct 15, 2026Open-market sale7,066 shares · $108K
    Avg. price $15.2789,229 shares held after
  • Huizenga Theodore AlanSVP, Chief Accounting Officer · Sep 15, 2026Open-market sale1,283 shares · $17K
    Avg. price $13.5767,863 shares held after
  • Huizenga Theodore AlanSVP, Chief Accounting Officer · Sep 3, 2026Open-market sale161 shares · $2K
    Avg. price $13.9969,146 shares held after
  • Horn HowardChief Financial Officer · Aug 3, 2026Open-market sale4,696 shares · $117K
    Avg. price $24.9296,295 shares held after
  • Parschauer Karah HerdmanEVP and Chief Legal Officer · Aug 3, 2026Open-market sale1,900 shares · $47K
    Avg. price $24.9292,562 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Ultragenyx Pharmaceutical (RARE) stock information

NASDAQ

Ultragenyx Pharmaceutical (RARE) is listed on NASDAQ. Its market capitalization is about $1.7B. On trailing-twelve-month earnings the P/E ratio is -3.25. These figures are computed in-house from official filings and are reference information only.

Ultragenyx Pharmaceutical — frequently asked questions

What is the P/E ratio of Ultragenyx Pharmaceutical (RARE)?
On a trailing-twelve-month basis, RARE trades at a P/E ratio of -3.25. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Ultragenyx Pharmaceutical?
RARE has a market capitalization of about $1.7B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.